Using these data, we were able to accurately predict the levels of exatecan derived from CBX-12 in tumor, with dosing of CBX-12 resulting in both a dose-dependent increase in exatecan and decrease in TOP1 protein levels in the tumor (Supplementary Figure S3a). The gene discussed is TOP1; the disease is neoplasm.